New York State Teachers Retirement System Sells 1,191 Shares of Axon Enterprise, Inc $AXON

New York State Teachers Retirement System reduced its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 1.9% during the third quarter, Holdings Channel.com reports. The fund owned 62,616 shares of the biotechnology company’s stock after selling 1,191 shares during the period. New York State Teachers Retirement System’s holdings in Axon Enterprise were worth $44,936,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. TFC Financial Management Inc. lifted its position in shares of Axon Enterprise by 8,666.7% in the 3rd quarter. TFC Financial Management Inc. now owns 263 shares of the biotechnology company’s stock worth $189,000 after purchasing an additional 260 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Axon Enterprise by 3.4% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 9,339 shares of the biotechnology company’s stock worth $6,702,000 after buying an additional 310 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in Axon Enterprise by 39.5% in the third quarter. Oregon Public Employees Retirement Fund now owns 8,945 shares of the biotechnology company’s stock valued at $6,419,000 after buying an additional 2,533 shares during the period. State of Alaska Department of Revenue lifted its holdings in Axon Enterprise by 1.6% in the third quarter. State of Alaska Department of Revenue now owns 8,445 shares of the biotechnology company’s stock valued at $6,060,000 after buying an additional 131 shares during the period. Finally, Capital Investment Advisors LLC boosted its position in Axon Enterprise by 3.1% during the third quarter. Capital Investment Advisors LLC now owns 1,069 shares of the biotechnology company’s stock valued at $767,000 after acquiring an additional 32 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Barclays lowered their price objective on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Northcoast Research raised Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 target price for the company in a research note on Tuesday, January 6th. JMP Securities reissued a “market outperform” rating and issued a $825.00 price target on shares of Axon Enterprise in a research note on Monday, September 29th. Morgan Stanley cut their price target on Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $870.00 price objective on shares of Axon Enterprise in a research note on Wednesday, September 24th. Fourteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $805.71.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, President Joshua Isner sold 20,000 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the transaction, the president owned 249,502 shares in the company, valued at approximately $137,874,805.20. This represents a 7.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Brittany Bagley sold 2,000 shares of the firm’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $580.00, for a total transaction of $1,160,000.00. Following the completion of the transaction, the chief financial officer directly owned 103,501 shares in the company, valued at $60,030,580. This trade represents a 1.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 60,540 shares of company stock worth $34,684,738 in the last ninety days. 4.40% of the stock is currently owned by corporate insiders.

Axon Enterprise Stock Up 3.1%

Shares of NASDAQ:AXON opened at $631.69 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. Axon Enterprise, Inc has a 52-week low of $469.24 and a 52-week high of $885.91. The business’s 50 day simple moving average is $572.86 and its two-hundred day simple moving average is $687.38. The firm has a market cap of $49.85 billion, a P/E ratio of 199.90, a PEG ratio of 19.89 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The firm had revenue of $710.64 million for the quarter, compared to the consensus estimate of $704.83 million. During the same quarter in the prior year, the firm earned $1.45 EPS. The company’s revenue was up 30.6% compared to the same quarter last year. As a group, research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.